 SIOUX FALLS, S.D., Dec. 15, 2022 GLOBE NEWSWIRE -- SAB Biotherapeutics Nasdaq: SABS, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting, an investor conference that drives biotech innovation and global collaboration through presentations delivered by innovative biotech companies, face-to-face networking and one-to-one meetings. The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference. 